Previous close | 3.4200 |
Open | 3.4100 |
Bid | 3.4100 x 500 |
Ask | 3.4400 x 500 |
Day's range | 3.3600 - 3.5300 |
52-week range | 2.0100 - 6.1300 |
Volume | |
Avg. volume | 994,533 |
Market cap | 263.069M |
Beta (5Y monthly) | 0.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.7800 |
Earnings date | 13 May 2024 - 17 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 12.89 |
The analysts covering Sutro Biopharma, Inc. ( NASDAQ:STRO ) delivered a dose of negativity to shareholders today, by...
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share. The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissi
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist